Meeting
2023 ASCO Annual Meeting
Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.
Authors
Amer Methqal Zeidan
Yale University, New Haven, CT
Amer Methqal Zeidan , Amir Tahmasb Fathi , Ghayas C. Issa , Harry Paul Erba , Julie Ahsan , Daniel Corum , Blake E. Tomkinson , Tom Kozlek , Mollie Leoni , Eunice S. Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04067336
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7079)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7079
Abstract #
TPS7079
Poster Bd #
206a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
First Author: Geoffrey L. Uy
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).
First Author: Tara L. Lin
Poster
2018 ASCO Annual Meeting
Trial in progress: An open-label, multicenter, phase 3b study to assess the safety and efficacy of midostaurin in patients (pts) aged ≥ 18 y with newly diagnosed (ND) FLT3-mutated acute myeloid leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy (chemo).
First Author: Adolfo Fuentes
Poster
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
First Author: Farhad Ravandi